Clonidine Restores Pressor Responsiveness to Phenylephrine and Angiotensin II in Ovine Sepsis.

Crit Care Med

1Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, Australia. 2Department of Physiology, Monash University, VIC, Australia. 3Department of Physiology, University of Lyon, Lyon, France. 4Department of Intensive Care, Austin Health, Heidelberg, VIC, Australia. 5Department of Medicine, Austin Health, Heidelberg, VIC, Australia. 6The Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia.

Published: July 2015

Objectives: In sepsis, prolonged, sympathetic overstimulation may lead to vasopressor-refractory hypotension. We therefore examined the effects of the α2-adrenergic agonist clonidine on mean arterial pressure, renal sympathetic nerve activity, and pressor responsiveness to phenylephrine and angiotensin II during hypotensive sepsis in conscious sheep.

Design: Interventional study.

Setting: Research institute.

Subjects: Twelve adult Merino ewes (n = 6 per group).

Interventions: Sepsis was induced by IV infusion of Escherichia coli for 32 hours. Pressor responses to increasing doses of phenylephrine and angiotensin II were measured at baseline and at 24, 28, and 32 hours of sepsis. Sheep were treated with clonidine (1 μg/kg/hr) or saline-vehicle from 24 to 32 hours of sepsis.

Measurements And Main Results: Sepsis was characterized by hypotension (~12 mm Hg), increased heart rate (~80 beats/min), increased renal sympathetic nerve activity (~70%), and blunted pressor responses to phenylephrine and angiotensin II. In vehicle-treated sheep, mean arterial pressure progressively declined from 25 to 32 hours of sepsis (73 ± 3 to 66 ± 3 mm Hg; p = 0.013) while the elevations in heart rate and renal sympathetic nerve activity and reduced pressor responsiveness to vasopressors persisted. Clonidine treatment prevented the further decline in mean arterial pressure, substantially reduced heart rate and renal sympathetic nerve activity and restored pressor responsiveness to both phenylephrine and angiotensin II toward preseptic levels.

Conclusions: Administration of clonidine during hypotensive sepsis reduced renal sympathetic nerve activity, restored vascular sensitivity to both phenylephrine and angiotensin II, and resulted in better preservation of arterial pressure. Considering these findings, a clinical trial for the use of clonidine in the treatment of persistent vasopressor-refractory hypotension in patients with septic shock would be worthwhile.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCM.0000000000000963DOI Listing

Publication Analysis

Top Keywords

phenylephrine angiotensin
24
renal sympathetic
20
sympathetic nerve
20
nerve activity
20
pressor responsiveness
16
arterial pressure
16
responsiveness phenylephrine
12
heart rate
12
sepsis
8
vasopressor-refractory hypotension
8

Similar Publications

Background: The dried root of Inula helenium L., known as Inulae Radix in Mongolian medicine, is a widely used heat-clearing plant drug within the Asteraceae family. Alantolactone (ATL), a compound derived from Inulae Radix, is a sesquiterpene lactone with a range of biological activities.

View Article and Find Full Text PDF

Coingestion of cardiovascular drugs with angiotensin-converting enzyme inhibitors (ACEIs) can be associated with refractory shock derangements complicated by vasopressor resistance, prompting the use of novel, unconventional, or uncommonly used agents. A young adult male presented to the emergency department (ED) 10 h after ingesting lisinopril and amlodipine. On arrival, he was hypotensive with a blood pressure of 72/39 mmHg.

View Article and Find Full Text PDF

Transcription Factor 21 Regulates Cardiac Myofibroblast Formation and Fibrosis.

Circ Res

January 2025

Division of Molecular Cardiovascular Biology (A.K.Z.J., R.K.K., R.J.V., S.-C.J.L., S.L.K.B., Y.K., K.M.G., K.W., M.A.S., T.A.B., J.D.M.), Department of Pediatrics, University of Cincinnati and Cincinnati Children's Hospital Medical Center, OH.

Background: TCF21 (transcription factor 21) is a bHLH (basic helix-loop-helix) protein required for the developmental specification of cardiac fibroblasts (CFs) from epicardial progenitor cells that surround the embryonic heart. In the adult heart, TCF21 is expressed in tissue-resident fibroblasts and is downregulated in response to injury or stimuli leading to myofibroblast differentiation. These findings led to the hypothesis that TCF21 regulates fibroblast differentiation in the adult mammalian heart to affect fibrosis.

View Article and Find Full Text PDF
Article Synopsis
  • - The study focused on myofibroblasts and how a vaccine targeting fibroblast activation protein (FAP) might help reduce cardiac fibrosis in mice with chronic cardiac stress.
  • - Mice were vaccinated with a FAP peptide while undergoing continuous treatment with angiotensin II and phenylephrine, resulting in a significant decrease in both cardiac fibrosis and the number of myofibroblasts.
  • - The findings suggest that the FAP vaccine is a promising therapeutic option for cardiac fibrosis without causing harmful side effects in other injury models, indicating its potential for future treatments.
View Article and Find Full Text PDF
Article Synopsis
  • Acute kidney injury (AKI) often occurs in patients with vasodilatory shock and is linked to higher mortality rates, longer hospital stays, and potential chronic kidney disease.
  • A comparison of catecholamine vasopressors (like norepinephrine and epinephrine) with non-catecholamine options (like vasopressin and angiotensin II) indicated that catecholamines could worsen kidney function and recovery.
  • Research showed that non-catecholamine vasopressors were associated with better renal outcomes, including lower serum creatinine levels and reduced need for kidney replacement therapy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!